Padmanabhan Ananthan

1 week ago | today.westlaw.com | Padmanabhan Ananthan |Leroy Leo

(Reuters) -Surgery Partners said on Tuesday it was unable to agree to the terms set by Bain Capital, its largest shareholder, to take the surgical facility operator private. Surgery Partners' shares fell more than 13% to $20.10 in premarket trading.

1 week ago | today.westlaw.com | Shinjini Ganguli |Bhanvi Satija |Padmanabhan Ananthan |Puyaan Singh

(Reuters) -Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only postpartum depression pill approved in the United States. The deal will help Supernus, which makes treatments for...

2 weeks ago | today.westlaw.com | Padmanabhan Ananthan |Puyaan Singh |Pooja Desai

(Reuters) -KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had extended the review of its drug for a type of hereditary swelling disorder due to heavy workload and limited resources. The FDA indicated that it now...

2 weeks ago | today.westlaw.com | Padmanabhan Ananthan |Shilpi Majumdar

(Reuters) -Drug distributor Cardinal Health raised annual adjusted profit forecast on Thursday, banking on resilient demand for costly specialty medicines and branded drugs at its pharmaceuticals unit. Demand for specialty medicines, which help treat...

1 month ago | today.westlaw.com | Padmanabhan Ananthan |Shailesh Kuber

(Reuters) -Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is launching a new share buyback program.